ARTICLES BY MICHAEL COOPER
-
![Large Diamond with Tweezers=iStock-1252617238]( "Decentralized Clinical Trials: Does Your Strategy Include These Facets?")
Decentralized Clinical Trials: Does Your Strategy Include These Facets?9/30/2021Decentralized clinical trials have increased in response to the COVID-19 pandemic, yet this may be due to a convergence of two factors already in play: our reliance on the use of digital health technologies and a move by the FDA and industry toward patient-focused, real-world clinical trials that leverage the technological advances already available.
Michael Cooper
Michael Cooper is a clinical and regulatory affairs program manager at Pharmatech Associates. He has over 20 years of experience in the biopharmaceutical industry, with expertise in regulatory affairs chemistry, manufacturing, and controls (CMC) submissions; GMP inspections for biologics and vaccines; QA lot release of drug substance and drug product; deviation and CAPA resolution; and facilities, utilities, and equipment validation.